Stocks and InvestingStocks and Investing
Thu, February 29, 2024
Wed, February 28, 2024

David Amsellem Maintained (SUPN) at Buy with Decreased Target to $41 on, Feb 28th, 2024


Published on 2024-10-28 09:17:50 - WOPRAI, David Amsellem
  Print publication without navigation


David Amsellem of Piper Sandler, Maintained "Supernus Pharmaceuticals, Inc." (SUPN) at Buy with Decreased Target from $45 to $41 on, Feb 28th, 2024.

David, nor any peers, have made any analyst calls on SUPN in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30